Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sTEADfast: VT3989 vs Chemotherapy in Advanced Epithelioid Mesothelioma
NCT07824986Phase 3Not yet recruiting
- Sponsor
- Vivace Therapeutics
- Start
- Dec 2026
- Primary completion
- May 2028
01
Overview
Phase 3, randomised, open-label trial of VT03989 in pleural mesothelioma (2 arms), sponsored by Vivace Therapeutics. Primary endpoint: Overall Survival. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
VT03989
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT07824986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824986.